

February 14, 1974

Robert Robinson, M.D.
A. H. Robins Co.
1407 Cummings Drive
Richmond, Virginia 23220

Dear Dr. Robinson,

We have completed the initial dose-finding studies of AHR-2277 and are satisfied that single 10 mg doses are safe and elicit systematic, dose-related EEG changes.

We have also completed the assays of the comparison substance, haloperidol, and are satisfied that single 6 mg doses elicit systematic effects. We believe that this dose may be above threshold, however, and we are exploring an additional group of subjects at 4 mg.

I am enclosing a copy of our work-sheets for your information. I have asked my staff to summarize the data of these initial studies and a report will be sent to you as soon as it is completed.

Should the 4 mg haloperidol doses be below threshold, we will undertake the comparison, classification study of placebo, AHR-2277, and haloperidol using 10 mg and 6 mg doses respectively. If the 4 mg dose of haloperidol is satisfactory, that dose will be used. In either case, the systematic study will begin before the end of February, and should be completed in 2 months.

Thank you for your patience, and my best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry